186 related articles for article (PubMed ID: 10531568)
1. Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Pession A; Prete A; Locatelli F; Bella S; Melchionda F; Garaventa A; Burnelli R; Paolucci G
Med Pediatr Oncol; 1999 Nov; 33(5):450-4. PubMed ID: 10531568
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
[TBL] [Abstract][Full Text] [Related]
4. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
[TBL] [Abstract][Full Text] [Related]
5. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
Papadopoulos KP; Garvin JH; Fetell M; Vahdat LT; Garrett TJ; Savage DG; Balmaceda C; Bruce J; Sisti M; Isaacson S; De LaPaz R; Hawks R; Bagiella E; Antman KH; Hesdorffer CS
Bone Marrow Transplant; 1998 Oct; 22(7):661-7. PubMed ID: 9818693
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Papadopoulos KP; Balmaceda C; Fetell M; Kaufman E; Vahdat LT; Bruce J; Sisti M; Isaacson S; De LaPaz R; Savage DG; Troxel A; Antman KH; Hesdorffer CS
J Neurooncol; 1999 Sep; 44(2):155-62. PubMed ID: 10619499
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
8. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
9. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
Sandler ES; Hagg R; Coppes MJ; Mustafa MM; Gamis A; Kamani N; Wall D
Med Pediatr Oncol; 2000 Oct; 35(4):403-9. PubMed ID: 11025470
[TBL] [Abstract][Full Text] [Related]
11. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
Fagioli F; Biasin E; Mastrodicasa L; Sandri A; Ferrero I; Berger M; Vassallo E; Madon E
Cancer; 2004 May; 100(10):2215-21. PubMed ID: 15139067
[TBL] [Abstract][Full Text] [Related]
12. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
Ozkaynak MF; Matthay K; Cairo M; Harris RE; Feig S; Reynolds CP; Buckley J; Villablanca JG; Seeger RC
J Clin Oncol; 1998 Mar; 16(3):937-44. PubMed ID: 9508176
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital.
Ilari I; De Ioris MA; Milano GM; Pessolano R; De Lurentis C; De Sio L; Fidani P; Jenkner A; Cozza R
Bone Marrow Transplant; 2010 Aug; 45(8):1274-80. PubMed ID: 20098456
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
Finlay JL; Goldman S; Wong MC; Cairo M; Garvin J; August C; Cohen BH; Stanley P; Zimmerman RA; Bostrom B; Geyer JR; Harris RE; Sanders J; Yates AJ; Boyett JM; Packer RJ
J Clin Oncol; 1996 Sep; 14(9):2495-503. PubMed ID: 8823328
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
Grodman H; Wolfe L; Kretschmar C
Pediatr Blood Cancer; 2009 Jul; 53(1):33-6. PubMed ID: 19326417
[TBL] [Abstract][Full Text] [Related]
17. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Grovas AC; Boyett JM; Lindsley K; Rosenblum M; Yates AJ; Finlay JL
Med Pediatr Oncol; 1999 Aug; 33(2):83-7. PubMed ID: 10398181
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
[TBL] [Abstract][Full Text] [Related]
20. Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: A second report.
Okada K; Yamasaki K; Nitani C; Fujisaki H; Osugi Y; Hara J
Pediatr Blood Cancer; 2019 Nov; 66(11):e27953. PubMed ID: 31393093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
